论文部分内容阅读
目的评价多西他赛联合克里唑替尼治疗晚期非小细胞肺癌的临床疗效和不良反应。方法按随机双盲原则将74例患者分为三组。A组给予多西他赛治疗;B组给予克里唑替尼治疗;C组给予多西他赛联合克里唑替尼治疗。观察三组患者的临床缓解率、1年生存率和中位生存期。结果 A组患者1年生存率为16.7%,中位生存期为6.8个月;B组患者1年生存率为20.8%,中位生存期为7.0个月;C组1年生存率为43.1%,中位生存期为10.3个月。C组1年生存率与中位生存期均显著优于A组和B组。C组患者血液毒性、胃肠道反应、神经系统障碍及脱发等不良反应发生率均显著低于A组和B组(P<0.05)。结论多西他赛联合克里唑替尼治疗晚期非小细胞肺癌疗效显著。
Objective To evaluate the clinical efficacy and adverse reactions of docetaxel combined with crizotinib in the treatment of advanced non-small cell lung cancer. Methods According to the randomized double-blind principle, 74 patients were divided into three groups. Group A received docetaxel treatment; Group B received crizotinib treatment; Group C received docetaxel combined with crizotinib treatment. The clinical remission rate, 1-year survival rate and median survival time of the three groups were observed. Results The 1-year survival rate was 16.7% in group A, and the median survival time was 6.8 months. The 1-year survival rate was 20.8% in group B, and the median survival time was 7.0 months. The 1-year survival rate in group C was 43.1% , The median survival was 10.3 months. The 1-year survival and median survival of group C were significantly better than those of group A and group B. The incidence of adverse reactions such as hematologic toxicity, gastrointestinal reaction, nervous system disorder and hair loss in group C were significantly lower than those in group A and group B (P <0.05). Conclusion Docetaxel combined with crizotinib treatment of advanced non-small cell lung cancer has a significant effect.